Cardioneuroablation for Neurocardiogenic Syncope

Phase

N/A

Condition

Orthostatic Hypotension

Cataplexy

Dizzy/fainting Spells

Treatment

N/A

Clinical Study ID

NCT02009982

IRB00062061

Ages > 18
All Genders

Study Summary

The purpose of this study is to evaluate the effectiveness of cardioneuroablation for the treatment of neurocardiogenic syncope (NCS), also known as "vaso-vagal" syncope. Syncope is a general term for passing out spells and neurocardiogenic syncope is a specific form of passing out spells caused by sudden drops in heart rate or blood pressure. Although the specific mechanisms of NCS are not well understood, it is believed that some people are prone to developing passing out spells in specific situations such as standing up for a long period of time, pain or nausea. In these situations, the body reacts with a paradoxical reflex which leads to a drop in blood pressure and heart rate and causes passing out. Certain types of medications are used to treat NCS including beta-blockers, midodrine and florinef, among others. However, none of these medications are particularly effective at preventing passing out spells and many people continue to have episodes despite trying different medications.

Cardioneuroablation is a new form of treatment for NCS. The term ablation means using a wire to make small electrical burns in the heart. Ablation has been used for many years to treat other electrical disturbances in the heart but the use of ablation to treat NCS is a new application. The goal of cardioneuroablation is to identify areas within the heart which are believed to initiate the reflex which triggers the drop in heart rate and blood pressure that leads to passing out. In preliminary studies, it has been suggested that cardioneuroablation may be significantly more effective than medications at preventing passing out spells for people with NCS.

Hypothesis: Cardioneuroablation of vagal inputs in the left atrium may serve as an effective treatment modality for the prevention of NCS by blunting the initial trigger of the cascade that leads to symptoms and syncope.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Subject is able and willing to sign and date the Patient Consent Form
Subject is 18 years of age or older
Subject is expected to remain available for the follow-up protocol
Subject is willing to comply with the follow-up procedures
Subject has medically documented history of neurocardiogenic syncope
Subject has had 3 episodes of syncope or presyncope in last 12 months
Subject has had a positive tilt table test, defined as the presence of syncope orpresyncope associated with abrupt hypotension (SBP < 70 mmHg) or bradycardia (HR < 40bpm), with or without sublingual nitroglycerin provocation or atropine challenge
Subject has been tried on at least one pharmacologic therapy for at least 4 weeks

Exclusion

Exclusion Criteria:

Subject has signs and symptoms of an active infection (i.e. fever, elevated whiteblood cell count, etc.) which has not been treated and/or has not demonstratedimprovement in white blood cell count and resolution of fever
Subject is pregnant or planning to become pregnant within the study protocol follow-up
Subject is enrolled or planning to participate in a concurrent drug and/or devicestudy during the course of this study that would confound study results as determinedby the study physician
Subject is unwillingly to comply with the randomization procedure
Subject has had no syncopal episodes in last six months while on medical therapy
Subject has one of the following conditions that is the documented source of syncope:sick sinus syndrome, sinus node or atrioventricular conduction deficiencies,ventricular tachyarrhythmias, pulmonary hypertension, hypertrophic cardiomyopathy,history of transient ischemic attack, seizure disorders, subclavian steal syndrome, ordrug-induced syncope
Subjects with a myocardial infarction within last six months
Subjects with severe heart failure (NYHA class III or IV), previous heart surgery,structural heart disease, or an infiltrative cardiac disease
Subject is contraindicated for left-atrial ablation, as determined by enrollingphysician

Study Design

December 01, 2013

December 31, 2015

Connect with a study center

Emory University
Atlanta, Georgia 30322
United States
Site Not Available
University of North Carolina
Chapel Hill, North Carolina 27599
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.